Physical and Functional Interactions between Cas and c-Src Induce Tamoxifen Resistance of Breast Cancer Cells through Pathways Involving Epidermal Growth Factor Receptor and Signal Transducer and Activator of Transcription 5b
Open Access
- 15 July 2006
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 66 (14), 7007-7015
- https://doi.org/10.1158/0008-5472.can-05-3952
Abstract
High expression of the adaptor molecule Cas has been linked to resistance to the antiestrogen tamoxifen, both in tissue culture and in human tumors. The aim of this study was to elucidate the mechanism(s) by which overexpression of Cas confers resistance to tamoxifen. Cas overexpression in MCF-7 breast cancer cells was shown to alleviate both tamoxifen-mediated growth inhibition and induction of apoptosis. This enhancement of cell proliferation/survival occurred in the absence of detectable effects on estrogen receptor (ER) transcriptional activity under conditions where tamoxifen was present, indicating that Cas-dependent tamoxifen resistance is not the result of a switch to an ER-negative phenotype or enhanced responses to the partial agonist activity of tamoxifen. Instead, we present evidence, suggesting that Cas promotes tamoxifen resistance by deregulation of alternative cell proliferation pathways, particularly those mediated through enhanced c-Src protein tyrosine kinase activity arising from Cas/c-Src interactions. Overexpression of Cas was found to drive endogenous c-Src into complex with Cas, a process that has been shown previously to cause up-regulation of c-Src tyrosine kinase activity. MCF-7 cells overexpressing Cas exhibited increased phosphorylation of two c-Src substrates, Tyr845 in the kinase domain of the epidermal growth factor receptor (EGFR) and signal transducer and activator of transcription (STAT) 5b. Importantly, Cas-dependent protection from the antiproliferative effects of tamoxifen was reversed by the expression of dominant inhibitory variants of these substrates (Y845F EGFR and COOH-terminally truncated STAT5b). Based on these findings, we suggest that the Cas/c-Src/EGFR/STAT5 signaling axis is a major regulator of tamoxifen-resistant breast cancer cell growth and survival. (Cancer Res 2006; 66(14): 7007-15)This publication has 37 references indexed in Scilit:
- Transactivating agonists of the EGF receptor require Tyr 845 phosphorylation for induction of DNA synthesisMolecular Carcinogenesis, 2005
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- The Prognostic Value of BCAR1 in Patients with Primary Breast CancerClinical Cancer Research, 2004
- Cancer Statistics, 2004CA: A Cancer Journal for Clinicians, 2004
- Antiestrogen resistance in breast cancer and the role of estrogen receptor signalingOncogene, 2003
- Synergistic Promotion of c-Src Activation and Cell Migration by Cas and AND-34/BCAR3Journal of Biological Chemistry, 2003
- Opposing Action of Estrogen Receptors α and β on Cyclin D1 Gene ExpressionOnline Journal of Public Health Informatics, 2002
- Novel Activation of STAT5b in Response to Epidermal Growth FactorOnline Journal of Public Health Informatics, 2002
- Processive Phosphorylation of p130Cas by Src Depends on SH3-Polyproline InteractionsJournal of Biological Chemistry, 2001
- Enhanced Phosphorylation of Src Family Kinase Substrates Containing SH2 Domain Binding SitesOnline Journal of Public Health Informatics, 1998